Ildong Begins R&D Transformation With 'Quick Win, Fast Fail' Strategy
Role For Internal/External Collaborations
Executive Summary
South Korea’s Ildong Pharmaceutical has begun a major transformation from an OTC-focused firm to an innovative R&D-based operation that aims to compete with global big pharma rivals, helped by both internal and external alliances, its R&D head says in an interview with Scrip.
You may also be interested in...
Ildong Joins Oral COVID-19 Drug Race Via Shionogi Partnership
Ildong has become the latest Korean pharma firm to start developing an oral COVID-19 drug in the country, potentially competing with Merck and Pfizer’s candidates which are now under approval review locally. The latest co-development deal is also set to expand the market prospects for the antiviral's Japanese originator.
Dawn Of A New Era? Korean Biopharma M&A Landscape Set For Change
Mergers and acquisitions are set to gain momentum in South Korea as firms outside the sector seek new growth engines and more open-minded biopharma companies seek rapid growth and globalization.
Korean Bio/Healthcare Sector Sees Ample Fund Inflows In 2021
Financing for Korean bioventures and pharma firms remained strong this year amid ample liquidity and strong investor sentiment in the sector. SK Bioscience's IPO was the top fundraiser in 2021, followed by HK inno.N’s offering, while GI Innovation raised the most money from venture capital sources.